Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Interferons and viruses induce a novel truncated ACE2 isoform and not the full-length SARS-CoV-2 receptor
Authors
Keywords
-
Journal
NATURE GENETICS
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2020-10-20
DOI
10.1038/s41588-020-00731-9
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS
- (2020) Yushun Wan et al. JOURNAL OF VIROLOGY
- Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19
- (2020) Daniel Blanco-Melo et al. CELL
- SARS-CoV-2 Receptor ACE2 Is an Interferon-Stimulated Gene in Human Airway Epithelial Cells and Is Detected in Specific Cell Subsets across Tissues
- (2020) Carly G.K. Ziegler et al. CELL
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor
- (2020) Markus Hoffmann et al. CELL
- Weak Induction of Interferon Expression by SARS-CoV-2 Supports Clinical Trials of Interferon Lambda to Treat Early COVID-19
- (2020) Thomas R O’Brien et al. CLINICAL INFECTIOUS DISEASES
- Comparative replication and immune activation profiles of SARS-CoV-2 and SARS-CoV in human lungs: an ex vivo study with implications for the pathogenesis of COVID-19
- (2020) Hin Chu et al. CLINICAL INFECTIOUS DISEASES
- COVID-19: A New Virus, but a Familiar Receptor and Cytokine Release Syndrome
- (2020) Toshio Hirano et al. IMMUNITY
- COVID-19 and emerging viral infections: The case for interferon lambda
- (2020) Ludmila Prokunina-Olsson et al. JOURNAL OF EXPERIMENTAL MEDICINE
- Triple combination of interferon beta-1b, lopinavir–ritonavir, and ribavirin in the treatment of patients admitted to hospital with COVID-19: an open-label, randomised, phase 2 trial
- (2020) Ivan Fan-Ngai Hung et al. LANCET
- Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
- (2020) Nicole M Kuderer et al. LANCET
- Case Fatality Rate of Cancer Patients with COVID-19 in a New York Hospital System
- (2020) Vikas Mehta et al. Cancer Discovery
- Differential expression of interferon-lambda receptor 1 splice variants determines the magnitude of the antiviral response induced by interferon-lambda 3 in human immune cells
- (2020) Deanna M. Santer et al. PLoS Pathogens
- Kallikrein-kinin blockade in patients with COVID-19 to prevent acute respiratory distress syndrome
- (2020) Frank L van de Veerdonk et al. eLife
- Interferon-α2b Treatment for COVID-19
- (2020) Qiong Zhou et al. Frontiers in Immunology
- The renin–angiotensin system: An integrated view of lung disease and coagulopathy in COVID-19 and therapeutic implications
- (2020) Betty Diamond JOURNAL OF EXPERIMENTAL MEDICINE
- Longitudinal analyses reveal immunological misfiring in severe COVID-19
- (2020) Carolina Lucas et al. NATURE
- COVID-19 severity correlates with airway epithelium–immune cell interactions identified by single-cell analysis
- (2020) Robert Lorenz Chua et al. NATURE BIOTECHNOLOGY
- Type I and III interferons disrupt lung epithelial repair during recovery from viral infection
- (2020) Jack Major et al. SCIENCE
- Type III interferons disrupt the lung epithelial barrier upon viral recognition
- (2020) Achille Broggi et al. SCIENCE
- Impaired Breakdown of Bradykinin and Its Metabolites as a Possible Cause for Pulmonary Edema in COVID-19 Infection
- (2020) Steven de Maat et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Critical Role of Type III Interferon in Controlling SARS-CoV-2 Infection in Human Intestinal Epithelial Cells
- (2020) Megan L. Stanifer et al. Cell Reports
- Immunophenotyping of COVID-19 and influenza highlights the role of type I interferons in development of severe COVID-19
- (2020) Jeong Seok Lee et al. Science Immunology
- COVID and the Renin-Angiotensin System: Are Hypertension or Its Treatments Deleterious?
- (2020) Florian Zores et al. Frontiers in Cardiovascular Medicine
- Elevated nucleoprotein-induced interferon-γ release in COVID-19 patients detected in a SARS-CoV-2 enzyme-linked immunosorbent spot assay
- (2020) Steven Thijsen et al. JOURNAL OF INFECTION
- PepQuery enables fast, accurate, and convenient proteomic validation of novel genomic alterations
- (2019) Bo Wen et al. GENOME RESEARCH
- IFN-λ4 Attenuates Antiviral Responses by Enhancing Negative Regulation of IFN Signaling
- (2017) Adeola A. Obajemu et al. JOURNAL OF IMMUNOLOGY
- Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them
- (2017) Kathrin Leppek et al. NATURE REVIEWS MOLECULAR CELL BIOLOGY
- miRNA-200c-3p is crucial in acute respiratory distress syndrome
- (2017) Qiang Liu et al. Cell Discovery
- Association of germline variants in the APOBEC3 region with cancer risk and enrichment with APOBEC-signature mutations in tumors
- (2016) Candace D Middlebrooks et al. NATURE GENETICS
- Nsite, NsiteH and NsiteM computer tools for studying transcription regulatory elements: Fig. 1.
- (2015) Ilham A. Shahmuradov et al. BIOINFORMATICS
- Angiotensin II plasma levels are linked to disease severity and predict fatal outcomes in H7N9-infected patients
- (2014) Fengming Huang et al. Nature Communications
- Angiotensin-converting enzyme 2 protects from lethal avian influenza A H5N1 infections
- (2014) Zhen Zou et al. Nature Communications
- A variant upstream of IFNL3 (IL28B) creating a new interferon gene IFNL4 is associated with impaired clearance of hepatitis C virus
- (2013) Ludmila Prokunina-Olsson et al. NATURE GENETICS
- A diverse range of gene products are effectors of the type I interferon antiviral response
- (2011) John W. Schoggins et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started